TCS Biosciences Ltd.

Home › Sepsis

Certificates of Analysis: Selectrol | Dyes & Stains

PliNOSa^® K-1600 Assay Kit

An Innovation for Sepsis Screening

TCS Biosciences Ltd is pleased to announce our partnership with R&D Antibodies. R&D Antibodies has delivered high quality research antibodies and immunoassays to the life sciences and research markets since 1984.

The PliNOSa^® K-1600 Assay Kit is a novel in vitro diagnostic immunoassay for the early identification of sepsis.

The PliNOSa^® test detects inducible Nitric Oxide Synthase (iNOS) on microvesicles in plasma, an innovation in sepsis disease pathology.

The PliNOSa^® test can help physicians make better and more informed choices for improved patient management.

iNOS has specifically been implicated in sepsis, severe sepsis and septic shock. The PliNOSa^® K-1600 assay kit provides accurate measurement of circulating iNOS concentrations in plasma samples via a chemiluminescent sandwich EIA. Each kit is for 96 tests.

PliNOSa^® features:

Detects circulating iNOS in plasma.
Novel biomarker directly involved in sepsis pathology.
The assay is CE marked.
Standards and controls are provided.

Test benefits:

Can identify patients at risk as early as 48 hours before clinical symptoms appear.
Easy to use ELISA test with 8-well strips (x12) for efficiency.
Compatible with most EIA washers.

The kit includes:

12 x 8 well strips with immobilized anti-iNOS capture monoclonal antibody
HRP-labelled anti-iNOS detection monoclonal antibody
Wash buffer
Assay buffer
Diluents
Standards and controls

Table 1 - Organ Dysfunction Associated with Sepsis in Severely Injured Trauma Patients
N = 187		Heart, Lung or Kidney Dysfunction
		Present	Absent
iNOS	Positive	107	5
	Negative	15	60
Sensitivity = 88%		PPV = 96%
Specificity = 92%		NPV = 80%

The Sepsis Pathology via Microvesicles

Until now, sepsis has been an intractable disease that has baffled medical researchers for centuries.

Biochemical markers such as procalcitonin (PCT), IL-6, lactate and CRP have lacked the necessary specificity and sensitivity. These assays often fail to help physicians and clinicians to identify at-risk patients who are progressing down the sepsis pathway.

The PliNOSa^® test helps physicians assess a patient's risk of developing sepsis as much as 48 hours before recognisable symptoms appear.

Contact us for more information